Paid Clinical Trials Fort Worth

Discover 1,870 paid clinical trials in Fort Worth. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,870

Investigational CMV Vaccine Study for Volunteers Ages 9–15

PHASE1

PHASE2

Sponsor:

Moderna

Location:

Fort Worth, Norman, Austin, Edmondshow 42 more

Code:

NCT05575492

Conditions

Cytomegalovirus

Eligibility Criteria

Sex: All

Age: 9 - 15

Healthy Volunteers: Accepted

Interventions

mRNA-1647

Placebo

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Dallas, Plano, Oklahoma City, Houstonshow 47 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

Evaluating Pathways Mutual Gaze Protocol on Social Skills in Young Children Suspected of Autism

Recruiting

Sponsor:

The University of Texas at Dallas

Location:

Richardson

Code:

NCT06596226

Conditions

Autism

Eligibility Criteria

Sex: All

Age: 16 - 30

Healthy Volunteers: Not accepted

Interventions

Pathways Parent Mediated Intervention

Pathways Parent Mediated Intervention without Mutual Gaze

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease

Recruiting

PHASE1

PHASE2

Sponsor:

Ocugen

Location:

Dallas, Bellaire, Jackson, Phoenixshow 2 more

Code:

NCT05956626

Conditions

Stargardt Disease

Eligibility Criteria

Sex: All

Age: 6 - 65

Healthy Volunteers: Not accepted

Interventions

OCU410ST

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Recruiting

Sponsor:

CAGE Bio Inc.

Location:

Fort Worth

Code:

NCT05202366

Conditions

Fungal Infection

Onychomycosis

Tinea Unguium

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

CGB-400 Topical Gel

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Recruiting

PHASE1

PHASE2

Sponsor:

OncoResponse, Inc.

Location:

Irving, Austin, San Antonio, Fairfax

Code:

NCT06090266

Conditions

Cancer

Tumor, Solid

Malignant Neoplasm

Metastatic Cancer

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OR502

Cemiplimab

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Recruiting

PHASE1

PHASE2

Sponsor:

Jazz Pharmaceuticals

Location:

Dallas, Houston, Memphis, Cincinnatishow 9 more

Code:

NCT05734066

Conditions

Refractory Ewing Sarcoma

Relapsed Ewing Sarcoma

Ewing Sarcoma

Eligibility Criteria

Sex: All

Age: 2 - 30

Healthy Volunteers: Not accepted

Interventions

Lurbinectedin

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Lewisville, Frisco, Oklahoma City, Fort Smithshow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Lewisville, Dallas, Plano, Wylieshow 195 more

Code:

NCT06283966

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

BGF MDI 320/14.4/9.6 μg

GFF MDI 14.4/9.6 μg

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Recruiting

PHASE1

PHASE2

Sponsor:

Amgen

Location:

Irving, Dallas, Tyler, Houstonshow 8 more

Code:

NCT05325866

Conditions

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bemarituzumab

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

DeSoto, Dallas, Boerne, Kingwoodshow 64 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA